Saltar al contenido
Merck
Todas las fotos(3)

Key Documents

View All Documentation

E4876

Sigma-Aldrich

17α-etinilestradiol

≥98%

Sinónimos:

17α-etinil-1,3,5(10)-estratrieno-3,17β-diol, 19-Nor-1,3,5(10),17α-pregnatrien-20-ino-3,17-diol, Etinilestradiol

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(3)

About This Item

Fórmula empírica (notación de Hill):
C20H24O2
Número de CAS:
57-63-6
Peso molecular:
296.40
Beilstein/REAXYS Number:
2419975
EC Number:
200-342-2
MDL number:
MFCD00003690
UNSPSC Code:
12352200
PubChem Substance ID:
24894585
NACRES:
NA.77

biological source

synthetic

sterility

non-sterile

assay

≥98%

form

powder

mp

182-183 °C (lit.)

solubility

ethanol: 50 mg/mL, clear, colorless to faintly yellow

shipped in

ambient

storage temp.

room temp

SMILES string

[H][C@]12CC[C@@]3(C)[C@@]([H])(CC[C@@]3(O)C#C)[C@]1([H])CCc4cc(O)ccc24

InChI

1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1

InChI key

BFPYWIDHMRZLRN-SLHNCBLASA-N

Gene Information

human ... ESR1(2099)
rat ... Afp(24177) , Esr1(24890) , Shbg(24775)

¿Está buscando productos similares? Visita Guía de comparación de productos

General description

17α-Ethynylestradiol (EE2) is a synthetic hormone. It is a derivative of estradiol (E2). It is implicated in estrogen replacement therapy and suspension of breastfeeding. EE2 is used to treat osteoporosis, menopausal and postmenopausal syndrome. It is also used to treat prostatic cancer and breast cancer in postmenopausal women. EE2 functions as an endocrine-disrupting chemical (EDC).

Application

17α-Ethynylestradiol has been used to study the effect of exogenous estrogen and selective estrogen receptor modulator (SERM) in rats. It also has been used to increase the concentration of low density lipoprotein (LDL) receptor in rabbit liver.

Biochem/physiol Actions

17α-Ethynylestradiol is an orally bio-active synthetic estrogen used as an oral contraceptive.

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 1 - Carc. 2 - Repr. 1A

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

ppe

Eyeshields, Gloves, type P3 (EN 143) respirator cartridges

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Huda Omar Ali et al.
PloS one, 11(3), e0152114-e0152114 (2016-03-22)
Oestrogens influence the pathology and development of hormone-sensitive breast cancers. Tissue factor pathway inhibitor (TFPI) has been shown to be associated with breast cancer pathogenesis. Recently, we found TFPI mRNA levels to be significantly reduced by oestrogens in a breast
Richard Mark Evans et al.
PloS one, 7(8), e43606-e43606 (2012-08-23)
A growing body of experimental evidence indicates that the in vitro effects of mixtures of estrogenic chemicals can be well predicted from the estrogenicity of their components by the concentration addition (CA) concept. However, some studies have observed small deviations
Admane H Shanthanagouda et al.
PloS one, 9(2), e88165-e88165 (2014-02-14)
In human, a reduction in estrogen has been proposed as one of the key contributing factors for postmenopausal osteoporosis. Rodents are conventional models for studying postmenopausal osteoporosis, but the major limitation is that ovariectomy is needed to mimic the estrogen
Analysis of 17-beta-estradiol and 17-alpha-ethinylestradiol in biological and environmental matrices?a review
Barreiros L, et al.
Microchemical Journal, Devoted to the Application of Microtechniques in All Branches of Science, 126, 243-262 (2016)
Anders E A Dahm et al.
BMC cardiovascular disorders, 6, 40-40 (2006-10-13)
Hormone therapy, oral contraceptives, and tamoxifen increase the risk of thrombotic disease. These compounds also reduce plasma content of tissue factor pathway inhibitor-1 (TFPI), which is the physiological inhibitor of the tissue factor pathway of coagulation. The current aim was
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico